本报告导读： 电网投资规模持续扩大，同时公司通过收购亿力科技整合同业资源，在同业竞争消 除和行业政策利好的背景下，看好公司长期发展空间。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 7,615 | 7,673 | 8,470 | 9,858 | 11,339 | | (+/-)% | 2.0% | 0.8% | 10.4% | 16.4% | 15.0% | | 净利润（归母） | 801 | 828 | 913 | 1,089 | 1,275 | | (+/-)% | 18.3% | 3.4% | 10.3% | 19.2% | 17.1% | | 每股净收益（元） | 0.67 | 0.69 | 0.76 | 0.91 | 1.06 | | 净资产收益率(%) | 14.0% | 13.1% | 13.1% | 14.1% | 14.8% | | 市盈率(现价&最新股本摊薄） | 27.60 | 26.69 ...

Investment Rating - The report maintains a "Buy" investment rating for the company [8] Core Views - The company has signed a significant international contract worth approximately 4.06 billion USD (about 29.26 billion RMB) for an alumina project, which represents 190.53% of its 2024 revenue, ensuring performance growth [4] - The company has seen substantial revenue growth, with a 45.80% year-on-year increase in 2024 revenue to 1.536 billion RMB and a 53.80% increase in net profit to 157 million RMB [3][10] - The company is enhancing its production capacity through new projects, including a digital twin intelligent conveyor production base in Tangshan, which is expected to add 40,000 meters of capacity [5] - A partnership with Huawei has led to the development of the "Mine Intelligent Industrial Inspection Robot V1.0," integrating advanced technologies such as AI and big data [6][7] Summary by Sections Financial Performance - In Q1 2025, the company reported a revenue of 407 million RMB, a 54.02% increase year-on-year, and a net profit of approximately 38.88 million RMB, up 27.30% [3] - Forecasted revenues for 2025-2027 are 2.136 billion RMB, 2.835 billion RMB, and 3.635 billion RMB, respectively, with corresponding EPS of 1.50, 2.19, and 2.97 RMB [8][10] Capacity Expansion - The company has successfully launched projects aimed at alleviating capacity shortages, including an energy-saving and environmentally friendly project [5] - The Tangshan base is being constructed to high standards and is expected to enhance the company's competitive edge through automation and digital upgrades [5] Strategic Partnerships - The collaboration with Huawei aims to leverage AI and advanced technologies to create innovative industrial solutions, enhancing the company's product offerings [6][7]

Investment Rating - The report maintains a "Buy" investment rating for Longbai Group (002601.SZ) [1] Core Views - Longbai Group, as a leader in the titanium industry, has shown steady growth and established scale advantages that create long-term barriers to entry [5] - The company achieved a total revenue of 27.539 billion yuan in 2024, a year-on-year increase of 2.78%, while the net profit attributable to shareholders decreased by 32.79% to 2.169 billion yuan [4][8] - In Q1 2025, the company reported a revenue of 7.060 billion yuan, a year-on-year decline of 3.21%, but a quarter-on-quarter increase of 6.10% [4] Summary by Sections Market Performance - Longbai Group's performance is compared to the CSI 300 index, showing fluctuations in stock performance [3] Financial Performance - In 2024, the company produced 1.2955 million tons of titanium dioxide, a year-on-year increase of 8.74%, and sold 1.2545 million tons, a year-on-year increase of 8.25% [5] - The revenue from titanium dioxide accounted for 69% of total revenue, while sponge titanium production increased by 34.56% to 69,700 tons [5] - The company’s operating cash flow increased by 11.54% to 3.797 billion yuan in 2024 [6] Research and Development - Longbai Group is advancing in the new energy materials sector, with breakthroughs in high-performance lithium iron phosphate and artificial graphite materials [7] - The company is working on projects to produce 200,000 tons of lithium-ion battery anode materials and 200,000 tons of lithium iron phosphate [7] Profit Forecast - The forecast for net profit attributable to shareholders for 2025-2027 is 3.187 billion, 3.752 billion, and 4.110 billion yuan respectively, with corresponding P/E ratios of 12.4, 10.5, and 9.6 [8][10]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2][6][7] Core Views - The company's main business operations remain stable, with significant achievements in educational publishing and digital transformation [6] - The company reported a revenue of 9.172 billion yuan in 2024, a decrease of 2.07% year-on-year, while the net profit attributable to shareholders was 810 million yuan, down 36.91% year-on-year [6][7] - The company has a strong cash reserve of 2.314 billion yuan as of Q1 2025 and has implemented an active dividend policy, distributing a total of 1.384 billion yuan in cash dividends over the past three years [6][7] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 91.72 billion yuan, with a year-on-year decrease of 2.07% due to various factors including changes in consumer habits and reduced income from after-school services [6] - The revenue from textbooks and educational materials was 84.62 billion yuan, an increase of 1.91% year-on-year, while general book revenue was 18.14 billion yuan, a decrease of 7.98% [6] - The company’s net profit attributable to shareholders was 8.10 billion yuan, reflecting a significant decline of 36.91% year-on-year, primarily due to one-time impacts from tax and accounting adjustments [6][7] Future Outlook - The report forecasts the company's net profit attributable to shareholders for 2025-2027 to be 11.80 billion yuan, 12.84 billion yuan, and 13.26 billion yuan respectively, with corresponding PE ratios of 13.4, 12.3, and 11.9 [6][7] - The company is expected to benefit from the extension of tax incentives for state-owned publishing enterprises in 2025, which will eliminate the impact of income tax expenses [6] Market Position - The company has enhanced its digital capabilities, becoming the first in the country to include digital textbooks in the free teaching materials directory, and has significantly increased the issuance of its learning cards [6] - The company has also expanded its international presence, with 319 types of book copyrights exported, including successful exports to Southeast Asia [6]

证券研究报告 | 公司点评报告 2025 年 05 月 06 日 百普赛斯（301080.SZ） 业绩环比持续改善，国内业务复苏明显 消费品/生物医药 目标估值：NA 当前股价：47.18 元 基础数据 | 总股本（百万股） | 120 | | --- | --- | | 已上市流通股（百万股） | 91 | | 总市值（十亿元） | 5.7 | | 流通市值（十亿元） | 4.3 | | 每股净资产（MRQ） | 21.8 | | ROE（TTM） | 5.1 | | 资产负债率 | 7.6% | | 主要股东 | 陈宜顶 | | 主要股东持股比例 | 23.53% | 股价表现 公司发布 2024 年报和 2025 一季报：2024 年实现收入 6.45 亿元、归母净利润 1.24 亿元、扣非归母净利润 1.19 亿元，同比分别增长 18.65%、-19.38%、 -15.16%。其中 2024Q4 实现收入 1.82 亿元、归母净利润 4034.24 万元、扣非 归母净利润 3557.61 万元，同比分别增长 38.50%、58.60%、122.31%。2025Q1 实现收入 1.86 亿元、归母净利润 ...

上 市 公 司 公用事业 2025 年 05 月 06 日 国投电力 (600886) ——水电高发 Q1 业绩稳健 火电量价短期承压 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 05 月 06 日 | | --- | --- | | 收盘价（元） | 14.91 | | 一年内最高/最低（元） | 19.21/13.72 | | 市净率 | 1.8 | | 息率（分红/股价） | 3.32 | | 流通 A 股市值（百万元） | 111,142 | | 上证指数/深证成指 | 3,316.11/10,082.34 | | 注："息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 8.17 | | 资产负债率% | 61.26 | | 总股本/流通 A 股（百万） | 8,004/7,454 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 05-06 06-06 07-06 08-06 09-06 10-06 11-06 12-06 01-06 ...

AI-COP 再升级，智能体加速需求释放 致远互联(688369) ——2024 年年报与 2025 年 1 季报点评 股票研究 /[Table_Date] 2025.04.27 2025-05-06 计算机 [Table_Industry] /信息科技 [Table_Invest] 评级： 优于大市 [Table_Target] 目标价格： 35.27 [Table_CurPrice] 当前价格： 27.30 [Table_Market] 交易数据 [Table_Trend] 升幅(%) 1M 3M 12M 绝对升幅 -21% 20% 44% 相对指数 -18% 18% 36% 2024-04 2024-08 2024-12 2025-04 证 券 研 究 请务必阅读正文之后的免责条款部分 股 票 本报告导读： 公司 AI-COP 持续升级，新推出智能体产品线 CoMi，有望加速客户应用 AI Agent 需 求释放，在智能化、信创化发展机遇下，公司业绩有望逐步改善。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 20 ...

Investment Rating - The investment rating for Mindray Medical (300760) is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on growth in international markets and product advancements [1][2]. Core Insights - The report highlights that Mindray Medical achieved a revenue of 36.726 billion yuan in 2024, representing a year-over-year growth of 5.14%. The net profit attributable to the parent company was 11.668 billion yuan, with a slight increase of 0.74% [1]. - The domestic market faced challenges due to weak hospital procurement demand, while international markets benefited from localization efforts and high-end breakthroughs, leading to a 21.28% increase in international revenue [2]. - The IVD (In Vitro Diagnostics) segment remains a key growth driver, with a revenue increase of 10.82% in 2024, and significant international growth exceeding 30% [2][3]. Summary by Sections Financial Performance - In 2024, Mindray Medical's total revenue was 36.726 billion yuan, with a net profit of 11.668 billion yuan. The first quarter of 2025 saw a revenue of 8.237 billion yuan, down 12.12% year-over-year, and a net profit of 2.629 billion yuan, down 16.81% [1][2]. - The projected revenues for 2025-2027 are 40.422 billion yuan, 45.799 billion yuan, and 52.473 billion yuan, with corresponding growth rates of 10.1%, 13.3%, and 14.6% [5]. Business Segments - The IVD business generated 13.765 billion yuan in 2024, marking a 10.82% increase and solidifying its position as the largest business segment. International IVD revenue grew over 30% [2][3]. - The medical imaging segment achieved a revenue of 7.498 billion yuan in 2024, with international growth exceeding 15% [2]. - The life information and support segment faced a decline of 11.11% in revenue, but international markets showed double-digit growth due to high-end customer breakthroughs [2]. Market Dynamics - The report indicates that the domestic market is under pressure, but the international market is thriving due to localization and high-end product breakthroughs, with Asia-Pacific and European regions showing growth rates of 40% and 30%, respectively [2]. - The integration of AI technology across all business lines is expected to enhance competitiveness and market share, with significant advancements in IVD, medical imaging, and life information segments [2][3].

证券研究报告|电子 [Table_Title] 2024Q4 营收规模超百亿，先进封装盈利能 力有望提升 投资要点: ⚫ 2024Q4 单季度营收超百亿，再创单季度营收新高：2024 年第四季度， 营收方面，公司实现单季度营业收入 109.84 亿元，同比+18.99%，环比 +15.73%；毛利率方面，2024Q4 单季度毛利率为 13.34%，同比+0.17pct， 环比+1.11pct；营收再创单季度历史新高，毛利率有所提升，主要系下 游需求持续复苏，产能利用率提升。期间费用方面，2024Q4 销售费用 率 / 管 理 费 用 率 / 研 发 费 用 率 / 财 务 费 用 率 分 别 为 0.60%/3.58%/4.43%/0.32%，同比分别+0.05pct/+1.25pct/+0.55pct/- 0.93pct，期间费用整体同比+0.92pct；净利率方面，2024Q4 单季度净 利率为 4.93%，同比-0.45pct，环比+0.15pct，毛利率上升但净利率下 降，主要系费用率增长所致。归母净利润方面，2024Q4 公司实现归母 净利润 5.33 亿元，同比+7.28%，环比+16.63%。现 ...

采浆量稳健增长，控费水平提升 3 月 29 日，公司发布 2024 年年报。2024 年，公司实现总营业收入 60.32 亿元（+16.44%）；实现归母净利润 15.49 亿元（+39.58%）。 4 月 26 日，公司发布 2025 年一季报。2025Q1，公司实现总营业收入 13.18 亿元（+7.84%）,实现归母净利润 2.44 亿元（-22.90%），主要是 因为产品价格下降减少的利润大于销量增长增加的利润。 投资要点: 浆站和采浆量：公司下属成都蓉生以 1.85 亿美元总金额完成中原瑞德 100%股权的收购，公司新增一家血液制品生产企业，新增 5 个在营单采 血浆站，年采浆量增加百余吨。截至 2024 年，公司下属单采血浆站分 布于全国 16 个省/自治区，单采血浆站总数达 107 家，其中在营单采血 浆站数量达 85 家，实现血浆采集 2,781 吨（+15.15%），保持国内行业 占比约 20%。浆站数量和血浆采集规模均持续保持国内领先。 血制品收入：截至 2024 年，公司共计拥有人血白蛋白、人免疫球蛋白、 人凝血因子等三大类、15 个品种、90 个血液制品生产文号，公司下辖 成都蓉生、兰 ...